📍 Krascendo 1 🫁 #krasg12c #nsclc #esmo2026 #presidentialSymposium2
Phase 3, global, randomised trial of divarasib vs sotorasib or adagrasib in advanced/metastatic KRAS G12C-mutated NSCLC.
🍁Results🍀
-A significant benefit in PFS (HR: 0.58; 95% CI: 0.44–0.76), 9.8 vs 5.7 months for diva vs soto/ ada .
-A significant benefit in OS (HR: 0.56; 95% CI: 0.41–0.78) , 17.7 vs 11 months for diva vs soto/ ada
-A significant improvement in ORR was seen for diva (58.4%) vs soto/ ada (32.3%)
@myESMO @HemOncFellows @IMG_Oncologists @hemeoncfellow
5 views · 0 likes · 0 reposts · 0 replies
Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.orgKRASCENDO-1
https://esmocongress.esmo.orgSource: Sakditad “Tew” Saowapa, MD · x.com